Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
Standard
Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. / Minner, Sarah Jane Pauline; Kraetzig, Franziska; Tachezy, Michael; Kilic, Ergün; Graefen, Markus; Wilczak, Waldemar; Bokemeyer, Carsten; Huland, Hartwig; Sauter, Guido; Schlomm, Thorsten.
In: HUM PATHOL, Vol. 42, No. 12, 12, 2011, p. 1946-1952.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
AU - Minner, Sarah Jane Pauline
AU - Kraetzig, Franziska
AU - Tachezy, Michael
AU - Kilic, Ergün
AU - Graefen, Markus
AU - Wilczak, Waldemar
AU - Bokemeyer, Carsten
AU - Huland, Hartwig
AU - Sauter, Guido
AU - Schlomm, Thorsten
PY - 2011
Y1 - 2011
N2 - Activated leukocyte cell adhesion molecule (CD166) is a member of the immunoglobulin superfamily and is aberrantly expressed in different tumors, including prostate cancer. To learn more on the prevalence and clinical significance of activated leukocyte cell adhesion molecule expression in prostate cancer, a tissue microarray containing 3261 primary prostate cancers treated by radical prostatectomy was used. A total of 2390 different prostate cancers were analyzed by immunohistochemistry in a tissue microarray format. Activated leukocyte cell adhesion molecule immunostaining in cancers was compared with clinical follow-up, which was available for 1746 patients. Membranous activated leukocyte cell adhesion molecule immunostaining was recorded in 1663 (69.6%) of cases. High activated leukocyte cell adhesion molecule expression levels were significantly associated with favorable tumor features (pT: P = .0015; pN: P = .0008; preoperative prostate-specific antigen: P = .0057) and a lower risk of a biochemical recurrence (P = .0067). Cytoplasmatic activated leukocyte cell adhesion molecule staining was usually associated with membranous staining. The small number of cancers with pure cytoplasmatic staining did not reveal any particularities with respect to clinical outcome or tumor phenotype. It is concluded that activated leukocyte cell adhesion molecule protein is almost always expressed in prostate cancer and that decreased levels of activated leukocyte cell adhesion molecule expression may lead to an aggressive behavior of tumor cells. The abundant presence of activated leukocyte cell adhesion molecule and its membranous localization in prostate cancer epithelium make activated leukocyte cell adhesion molecule a potentially attractive structure for targeted therapy.
AB - Activated leukocyte cell adhesion molecule (CD166) is a member of the immunoglobulin superfamily and is aberrantly expressed in different tumors, including prostate cancer. To learn more on the prevalence and clinical significance of activated leukocyte cell adhesion molecule expression in prostate cancer, a tissue microarray containing 3261 primary prostate cancers treated by radical prostatectomy was used. A total of 2390 different prostate cancers were analyzed by immunohistochemistry in a tissue microarray format. Activated leukocyte cell adhesion molecule immunostaining in cancers was compared with clinical follow-up, which was available for 1746 patients. Membranous activated leukocyte cell adhesion molecule immunostaining was recorded in 1663 (69.6%) of cases. High activated leukocyte cell adhesion molecule expression levels were significantly associated with favorable tumor features (pT: P = .0015; pN: P = .0008; preoperative prostate-specific antigen: P = .0057) and a lower risk of a biochemical recurrence (P = .0067). Cytoplasmatic activated leukocyte cell adhesion molecule staining was usually associated with membranous staining. The small number of cancers with pure cytoplasmatic staining did not reveal any particularities with respect to clinical outcome or tumor phenotype. It is concluded that activated leukocyte cell adhesion molecule protein is almost always expressed in prostate cancer and that decreased levels of activated leukocyte cell adhesion molecule expression may lead to an aggressive behavior of tumor cells. The abundant presence of activated leukocyte cell adhesion molecule and its membranous localization in prostate cancer epithelium make activated leukocyte cell adhesion molecule a potentially attractive structure for targeted therapy.
KW - Humans
KW - Male
KW - Aged
KW - Middle Aged
KW - Multivariate Analysis
KW - Immunohistochemistry
KW - Prognosis
KW - Survival Analysis
KW - Follow-Up Studies
KW - Odds Ratio
KW - Phenotype
KW - Gene Expression Regulation, Neoplastic
KW - Neoplasm Staging
KW - Tissue Array Analysis
KW - Prostatectomy
KW - Antigens, CD/metabolism
KW - Cell Adhesion Molecules, Neuronal/metabolism
KW - Fetal Proteins/metabolism
KW - Neoplasm Grading
KW - Prostate/immunology/metabolism/pathology
KW - Prostate-Specific Antigen/metabolism
KW - Prostatic Neoplasms/immunology/pathology/surgery
KW - Humans
KW - Male
KW - Aged
KW - Middle Aged
KW - Multivariate Analysis
KW - Immunohistochemistry
KW - Prognosis
KW - Survival Analysis
KW - Follow-Up Studies
KW - Odds Ratio
KW - Phenotype
KW - Gene Expression Regulation, Neoplastic
KW - Neoplasm Staging
KW - Tissue Array Analysis
KW - Prostatectomy
KW - Antigens, CD/metabolism
KW - Cell Adhesion Molecules, Neuronal/metabolism
KW - Fetal Proteins/metabolism
KW - Neoplasm Grading
KW - Prostate/immunology/metabolism/pathology
KW - Prostate-Specific Antigen/metabolism
KW - Prostatic Neoplasms/immunology/pathology/surgery
M3 - SCORING: Journal article
VL - 42
SP - 1946
EP - 1952
JO - HUM PATHOL
JF - HUM PATHOL
SN - 0046-8177
IS - 12
M1 - 12
ER -
